Binimetinib vs Trametinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MEK1/2 · full Non-Small Cell Lung Cancer pipeline
Binimetinib
Marketed by Pfizer and partners
NCT03915951 · Phase 2 · completed
This was a single-group, open-label study of 98 participants receiving encorafenib plus binimetinib, without randomization or a placebo or active-control arm. The primary imaging-based tumor-response endpoint was reported descriptively, so there was no controlled statistical comparison demonstrating that binimetinib improved outcomes.
Next expected readout: August 2027 · NCT05355701 (registry estimate)
No aligned efficacy figure on record for this race.
Trametinib
Marketed by Novartis and partners
NCT01362296 · Phase 2 · completed
This was a randomized, active-controlled trial against a standard chemotherapy comparator, but it was conducted without blinding, and the primary progression-free-survival endpoint was not statistically different between arms (hazard ratio 1.14, 95% CI 0.75 to 1.75, p=0.5197).
Next expected readout: July 2027 · NCT03333343 (registry estimate)
Reported efficacy
Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20 (not_applicable)
Result source: NCT01336634
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Binimetinib | Trametinib |
|---|---|---|
| PFS, median | —Not reported | 2.7 vs 2.6vs DocetaxelNCT013622965 other results
|
| OS, median | —Not reported | 8.1 vs 9.9vs DocetaxelNCT013622964 other results
|
| ORR | 74.6%bNCT039159513 other results
| —Not reported |
| Duration of response, median | —Not reported | 1.6 vs 2.9vs DocetaxelNCT013622965 other results
|
PFS, median
- Binimetinib
- —Not reported
- Trametinib
- 2.7 vs 2.6vs DocetaxelNCT01362296
5 other results
- 10.2 NCT01336634
- 10.8 NCT01336634
- 5.4 NCT01336634
- 11 NCT01336634
- 13.9 NCT04452877
OS, median
- Binimetinib
- —Not reported
- Trametinib
- 8.1 vs 9.9vs DocetaxelNCT01362296
4 other results
- 18.2 NCT01336634
- 17.3 NCT01336634
- 12.7 NCT01336634
- 25.3 NCT04452877
ORR
- Binimetinib
- 74.6%bNCT03915951
3 other results
- 46.2% NCT03915951
- 62.7% NCT03915951
- 41% NCT03915951
- Trametinib
- —Not reported
Duration of response, median
- Binimetinib
- —Not reported
- Trametinib
- 1.6 vs 2.9vs DocetaxelNCT01362296
5 other results
- 9.8 NCT01336634
- 10.2 NCT01336634
- 11.8 NCT01336634
- 14.9 NCT04452877
- 13.4 NCT01336634
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Binimetinib: 3 of 4 rows · Trametinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Binimetinib | Trametinib |
|---|---|---|
| Dropout rate | n/a: no completion milestonePreviously Treated NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 1 more resultn/a: no completion milestoneTreatment-Naive NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 | —2 mga NCT01362296 · Phase 2 show 8 more resultsn/a: no completion milestone2 mg NCT01362296 · Phase 2 16.7%150mg BID NCT01336634 · Phase 2 · monotherapy 14%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 25%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination —DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 77.5%Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 15.4%Previously Treated NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 1 more result20.3%Treatment-Naive NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 | —2 mga NCT01362296 · Phase 2 show 8 more results23%2 mg NCT01362296 · Phase 2 —150mg BID NCT01336634 · Phase 2 · monotherapy —DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination —DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination —DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 12.5%Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 43.6%Previously Treated NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 1 more result42.4%Treatment-Naive NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 | 52.2%2 mga NCT01362296 · Phase 2 show 8 more results36.8%2 mg NCT01362296 · Phase 2 44%150mg BID NCT01336634 · Phase 2 · monotherapy 66.7%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 66.7%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination 45%DAB 150MG BID, TRA 2mG QD NCT01336634 · Phase 2 · combination —Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination 50%Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination 6.3%Dabrafenib in Combination With Tra NCT04452877 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | diarrhoea 51.3% nausea 48.7% fatigue 41% NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 1 more resultnausea 62.7% diarrhoea 49.2% fatigue 49.2% NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 | show 7 more resultsDAB 150MG BID, TRA 2mG QD pyrexia 61.1% nausea 58.3% diarrhoea 41.7% NCT01336634 · Phase 2 · combination anaemia 52.5% hypoalbuminaemia 47.5% pyrexia 45% NCT04452877 · Phase 2 · registry result, not featured evidence · combination hypoalbuminaemia 6.3% abdominal discomfort 0% abdominal pain upper 0% NCT04452877 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Binimetinib
show 3 more results
show 1 more result
show 1 more result
Trametinib
show 3 more results
show 4 more results
show 4 more results
show 3 more results
show 1 more result
+ 4 further endpoints in the CSV export.
Melanoma
Shared mechanism: MEK1/2 · full Melanoma pipeline
Binimetinib
Marketed by Pfizer and partners
NCT01763164 · Phase 3 · completed
The randomized, active-controlled trial compared binimetinib with dacarbazine in 402 participants, using progression-free survival assessed by RECIST as its primary clinical endpoint. Progression-free survival favored binimetinib (p<0.001), but the open-label design limits the strength of the evidence.
Next expected readout: January 2027 · NCT03947385 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71) (met)
Result source: NCT01763164
Trametinib
Marketed by Novartis and partners
NCT02039947 · Phase 2 · completed
The study was open-label, nonrandomized, and had no comparator arm; all participants received dabrafenib plus trametinib. Although the primary intracranial response result was reported as 45 of 76 participants (59%), the uncontrolled design provides weak evidence for trametinib’s treatment effect.
Next expected readout: February 2027 · NCT04417621 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Melanoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Trametinib: registry results are on file for Melanoma, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Binimetinib's landscape · Trametinib's landscape